Skinny, Inc. Part 1: the Canadian connection to Ozempic
Dr. Daniel Drucker’s research helped pave the way for Ozempic, the blockbuster GLP-1 class drug. The endocrinologist has been researching the effects on Ozempic’s active ingredient semaglutide in the body for decades.Today he’ll show us around his lab and explain how a stout lizard kept in a freezer helped unlock the science behind a drug taken by more than a million Canadians.
Then, health reporter Kelly Grant tells us about rising obesity rates in Canada, and we’ll hear from a doctor who prescribes GLP-1s— and a patient who takes them.
After this episode was published, Dr. Stephen Glazer…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.